TQ-B3234

N/A

Report date: 2026/04/07 20:00:20
NME

Base Information

Drug NameTQ-B3234
Drug Alias NameTQ-B3234CT-034
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsNeurofibromatosis 1Neurofibroma, PlexiformNeurofibroma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShouyao Holding (Beijing) Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsNeurofibromatosis 1Neurofibroma, PlexiformNeurofibroma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A